Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
Phase 3
Completed
- Conditions
- Healthy
- Registration Number
- NCT02414412
- Lead Sponsor
- Pusan National University Hospital
- Brief Summary
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults. 58 subjects received 500 mg of Ulmus macrocarpa water extract per day or a placebo for 4 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
- subject has peripheral white blood cells between 4,000/Ul and 8,000/Ul
Exclusion Criteria
- History of renal disease
- History of diabetes mellitus
- History of immune disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method serum natural killer cell activity 1 month
- Secondary Outcome Measures
Name Time Method peripheral white blood cell 1 month serum tumor necrosis factor-alpha level 1 month serum interferon-gamma 1 month serum interleukins(1betta, 2,4,8,10, and 12) 1 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ulmus macrocarpa water extract's immune-modulating effects in NCT02414412?
How does Ulmus macrocarpa extract compare to standard immune-boosting supplements like vitamin C or zinc in clinical trials?
Which biomarkers correlate with enhanced immune response in NCT02414412's healthy adult participants?
What adverse events were reported in Pusan National University Hospital's Ulmus macrocarpa Phase 3 trial and how were they managed?
Are there synergistic combination therapies involving Ulmus macrocarpa extract for immune enhancement in preclinical or clinical studies?